Ulotaront

Some adverse events reported in preliminary clinical trials are somnolence, agitation, nausea, diarrhea, and dyspepsia. ==Pharmacology==

Pharmacodynamics The mechanism of action of ulotaront in the treatment of schizophrenia is unclear. However, it is thought to be an agonist at the trace amine-associated receptor 1 (TAAR1) and serotonin 5-HT1A receptors. It is also a partial agonist of the serotonin 5-HT1A receptor ( = 2,300nM; = 74.7%) and of the serotonin 5-HT1D receptor ( = 262nM; = 57.1%). Ulotaront decreases basal locomotor activity in rodents and this effect was absent in TAAR1 knockout mice. Conversely, ulotaront did not affect dextroamphetamine-induced hyperlocomotion. Similarly, it did not reverse apomorphine-induced climbing behavior. Pharmacokinetics The precise pharmacokinetic profile of ulotaront has not been reported, though the developer has suggested that the pharmacokinetic data supports once daily dosing. ==Research==

As of 2018, Sunovion, the maker of another antipsychotic called lurasidone (Latuda), is conducting clinical trials on ulotaront in partnership with the preclinical research company PsychoGenics. The US Food and Drug Administration (FDA) has granted ulotaront the breakthrough therapy designation. In addition to schizophrenia, ulotaront is also being studied for the treatment of psychosis associated with Parkinson's disease. In July 2023, the pharmaceutical company behind the drug announced that the drug had failed to outperform placebo in the treatment of acutely psychotic patients with schizophrenia, as measured by the PANSS. == See also ==